Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Bacterial biofilm disruption is a therapeutic strategy that aims to break down the protective matrix of bacterial biofilms, rendering the embedded bacteria more susceptible to antibiotics and host immune defenses. It is particularly relevant in chronic respiratory infections associated with cystic fibrosis, where biofilms contribute to persistent inflammation and antimicrobial resistance. Approaches include degrading matrix components like exopolysaccharides, eDNA, and structural proteins such as DNABII, as well as interfering with quorum sensing and inhibiting matrix synthesis.
Disrupting the biofilm matrix to expose bacteria to antibiotics and immune cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Bacterial Biofilm Disruption (N/A).